Assess whether biosimilarity is analytically justified (ce5807)

Situation

CMC comparability package for a site change arrived with a CRL citing manufacturing, not efficacy for 505(b)(2) development lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on biosimilarity is analytically justified in a labeling team facing a boxed-warning debate.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in CMC comparability package for a site change is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in CMC comparability package for a site change is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call.
• A labeling team facing a boxed-warning debate already contained a CRL citing manufacturing, not efficacy before CMC comparability package for a site change arrived; no new CMC and Development Pathways path.
• Provenance on CMC comparability package for a site change after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.